Protara Therapeutics, Inc.
TARAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The $137.7M market capitalization puts TARA squarely in micro-cap range for its industry. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Market Cap
$137.7M
Beta
1.47
P/E (TTM)
—
P/E (Fwd)
-1.38
EPS (TTM)
$-1.31
EPS (Fwd)
$-1.69
ROE
-45.8%
ROA
-28.8%
Cash
$142.5M
Total Debt
$2.7M
Free CF
-$40.5M
52W Change
-54.3%
Annual Financials
Cash vs Debt
Where TARA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TARA finished 44.92% below its 150-day moving average ($4.23) and 50.32% below its 200-day moving average ($4.69). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TARA overbought or oversold?
At the October 20, 2026 close, TARA's RSI(14) was 16.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $142.5M in cash comfortably exceeding the $2.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$40.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -45.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, TARA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TARA.